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ongHu@rutgers.edAbstract Prodrug design is an important part of drug discovery. Prodrugs can offer many
advantages over parent drugs such as increased solubility, enhanced stability, improved bioavail-
ability, reduced side effects, and better selectivity. Many prodrugs have been used successfully in
the clinic; examples include oseltamivir in anti-inﬂuenza therapy, enalapril in anti-hypertension
therapy, capecitabine in cancer therapy, and omeprazole in the treatment of peptic ulcer. A key step
in prodrug design is the incorporation of an activation mechanism that can convert the prodrug
into the active species in an efﬁcient and/or controlled manner to meet the needs of a given medical
application. Prodrug activation can be achieved through enzyme-mediated hydrolytic or oxido-
reductive processes while activation of some prodrugs may proceed through pure chemical
nonenzymatic processes. This review focuses on the hydrolytic enzymes that have been used in
prodrug activation, including transferases, hydrolases, and lyases.
& 2011 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.edica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
rved.
tute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
445 5291; fax: þ1 732 445 6312.
u (Long-qin Hu).
Yan-hui Yang et al.1441. Introduction
With the advance of new technologies such as combinatorial
and computational chemistry, more and more compounds are
being identiﬁed with extremely potent in vitro activity but are
found to be inactive in vivo. They may have the optimal
conﬁguration and conformation needed to interact with their
target receptor or enzyme, but they do not necessarily possess
the best molecular form and physicochemical properties
needed for their delivery to the site of action. Some of the
problems often encountered include (i) limited solubility and
poor chemical stability preventing the drug from being ade-
quately formulated, (ii) low or variable bioavailability due to
incomplete absorption across biological membranes or exten-
sive ﬁrst-pass metabolism, and (iii) lack of site speciﬁcity.
Prodrugs have been designed and used clinically to solve these
problems. A prodrug is inactive or much less active and has to
be activated in vivo to form the active drug molecule.
Prodrug design has proven to work for many pharmacologi-
cally active compounds or drugs in improving their physicochem-
ical and biological properties and their target selectivity. Currently,
5–7% of the drugs approved worldwide can be classiﬁed as
prodrugs, and approximately 15% of all new drugs approved each
year are prodrugs1. Prodrugs have been used in a wide variety of
therapeutic areas including anti-inﬂuenza, anti-hypertension, anti-
biotics, antiulcer, anticoagulant, anti-inﬂammatory, antifungal,
anesthetic, and anticancer. Many prodrugs have gained huge
clinical success. Activation of prodrugs can involve many enzymes
including oxidoreductases like CYP450 and DT-diaphorase as
well as hydrolytic enzymes like carboxylesterase and b-glucuroni-
dase2–6. This review will provide an overview of the enzymes
involved in the hydrolytic activation of prodrugs.2. Enzymes
2.1. Carboxylesterase
Carboxylesterases (CEs, EC 3.1.1.1) are members of the serine
hydrolase superfamily and they can efﬁciently hydrolyze a
variety of ester-, amide-, and carbamate-containing xenobio-
tics to their respective free acids. They act as an effective
biological barrier to limit the distribution of substrates that
might be toxic and facilitate their elimination by turning them
into more polar molecules.
Although carboxylesterases show varying activity and sub-
strate speciﬁcity, depending on species and location, they are
present virtually throughout the body, including intestines,
blood, brain, skin, and tumor. There are several different
isozymes of carboxylesterases; based on sequence homology
and similarity of characteristics, the isozymes have recently
been classiﬁed into ﬁve subfamilies, CES1, CES2, CES3, CES4,
and CES57. However, other names such as human liver
carboxylesterase 1 (hCE1), carboxylesterase 2 (hCE2), intest-
inal carboxylesterase (hiCE), and human brain carboxylester-
ase (hBr2) continue to be used in the literature. Biochemical
analysis indicated that CEs are efﬁcient at hydrolyzing small
substrates, but show vast differences with increasingly larger
substrates. For example, the human liver hCE1 was 100- to
1000-fold less efﬁcient at metabolizing CPT-11 than rabbit liver
rCE, even though the two enzymes have over 80% amino acid
identity8,9. Analysis of the crystal structures indicates that thesubstrate speciﬁcity of CEs is, in part, determined by con-
straints enforced by the dimensions of, and access to, the active
site10.
The carboxylesterases are involved in the activation of
various antiviral, anticancer, and antibiotic prodrugs. Several
representative esterase-activated prodrugs are shown in Fig. 1.
Irinotecan (1, CPT-11) is converted to its active metabolite,
7-ethyl-10-hydroxycamptothecin, which is an inhibitor of
topoisomerase I8,11; temocapril (2), a long-acting ACE inhibi-
tor, is quickly metabolized to the active dicarboxylic acid12;
dipivefrin (3), available as an ophthalmic solution for the
treatment of glaucoma, is hydrolyzed to epinephrine on
penetrating cornea13; lovastatin (4), and simvastain (5), used
to lower cholesterol in patients with hypercholesterolemia,
were hydrolyzed by hCE1 to form the hydroxy acid forms,
which inhibit the activity of HMG-CoA reductase14.
2.2. Acetylcholinesterase
Acetylcholinesterase (AChE, EC 3.1.1.7) can rapidly hydro-
lyze the neurotransmitter acetylcholine at cholinergic synapses
and neuromuscular junctions. AChE is an extrinsic mem-
brane-bound enzyme that projects into the synapse. It is
responsible for the elimination of ACh released from the
presynaptic nerve process in response to an action potential
and is critical for maintaining normal cholinergic function15,16.
AChE is widely expressed in many tissues throughout the body.
including skeletal muscle, many types of neurons in the central and
peripheral nervous systems, and numerous other cell types that are
targets of cholinergic nerves such as endocrine and exocrine
glands, smooth and cardiac muscle cells, and sensory organs
embedded in epithelia17. In humans, AChE is also expressed in
non-attached cells such as erythrocytes and lymphocytes. Several
prodrugs activated by AChE have been reported. For example,
butyryl ACV (6, Fig. 2) is an AChE-activated ester prodrug of
acyclovir (ACV), which is a synthetic purine nucleoside analog of
guanine and clinically used in the treatment of herpes simplex virus
infections because of its afﬁnity for the viral thymidine kinase18.
2.3. Butyrylcholinesterase
Butyrylcholinesterase (BChE, EC 3.1.1.8) is relatively abun-
dant in plasma and is sometimes referred to as the serum
cholinesterase. However, its physiological role remains
unclear. BChE can degrade a large number of ester-containing
compounds, including ester prodrugs19. The overall 3-D
structure of BChE is very similar to that of AChEs. However,
BChE does not form the same kind of dimer as observed in
structures of Torpedo californica AChE, mouse AChE, and
human AChE15,19. BChE has a broader substrate speciﬁcity
than AChE, and this difference in speciﬁcity can be explained
by BChE’s more spacious acyl binding pocket at the active site
and differences in amino acid residues19.
BChE exists predominantly in plasma as well as in various
tissues such as brain, muscle, kidney, intestine, retina, and
placenta. Several BChE-activated prodrugs have been developed.
Bambuterol (7) is slowly converted by BChE to terbutaline, a
b2-adrenoceptor agonist
20,21. Methylprednisolone acetate (8) can
be hydrolyzed by BChE to its active form—methylprednisolone, a
steroid anti-inﬂammatory agent22. Isosorbide diaspirinate (9), the
aspirin diester of isosorbide, is stable towards aqueous hydrolysis
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Enzyme-mediated hydrolytic activation of prodrugs 145and in the presence of a-chymotrypsin23. However, it undergoes
rapid hydrolysis in the presence of BChE as shown in Fig. 3.2.4. Paraoxonase
Paraoxonase (PON, EC 3.1.8.1) is a family of hydrolases that
include PON1, PON2, and PON3. PON1 is an importantesterase that can catalyze the hydrolysis of various arylesterase
and organophosphates. PON2 and PON3 share 60% sequence
identity with PON1, but, they lack or have very limited
arylesterase activities. On the other hand, PON2 and PON3
exhibit high lactonase activity. Human PON1 is synthesized in
the liver and secreted into the blood, while PON3 is similarly
expressed predominantly in the liver and at low levels in the
kidney24. In recent years, PON1 and its two known Q and R
Yan-hui Yang et al.146isoenzymes have been shown to possess both arylesterase and
organophosphatase activities, and play important roles in drug
metabolism and in the prevention of atherosclerosis25.
Pruliﬂoxacin (10), a lipophilic prodrug of uliﬂoxacin, is a
new oral ﬂuoroquinolone with a broad spectrum of in vitro
activity against various Gram-positive and Gram-negative
microorganisms. Its structure contains the skeletal quinolone
with a four-membered ring in the 1,2-position, including a
sulfur atom to increase antibacterial activity and an oxodiox-
olenylmethyl group in the 7-piperazine ring to improve its oral
absorption; it is immediately and quantitatively transformed
by hPON1 into the active metabolite uliﬂoxacin (Fig. 4)26,27.
Lactone-containing drugs, Lovastatin and Simvastatin, are all
substrates of hPON315,24,28.2.5. Matrix metalloproteinase
Matrix metalloproteinases (MMPs), also known as matrixins, are
zinc-dependent endopeptidases consisting of more than 25 family
members classiﬁed based on domain structure and substrate
speciﬁcity (Table 1). They play important roles in the degrada-
tion of extracellular matrix components, such as collagen,
laminin, ﬁbronectin, and elastin. MMPs also cleave a variety
of proteins, such as growth factor receptors and cell adhesion
molecules, which may be important for tumor growth and
survival. Synthesized initially as inactive proenzymes, MMPsN
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Table 1 Matrix metalloproteinases and their substrates.
Enzyme Alternative name EC number
MMP-1 Interstitial collagenase 3.4.24.7
MMP-2 Gelatinase A 3.4.24.24
MMP-3 Stromelysin-1, Proteoglycanase 3.4.24.17
MMP-8 Neutrophil collagenase 3.4.24.34
MMP-9 Gelatinase B 3.4.24.35
MMP-13 Collagenase-3 –
MMP-14 MT1-MMP 3.4.24.80
MMP-18 Xenopus Collagenase-4 –
MMP-22 Chicken MMP (C-MMP) –require proteolytic processing to produce their active forms that
usually consist of three main domains, namely a propeptide
domain, a catalytic domain, and a hemopexin/vitronectin-like
domain. Several MMPs, including MMP-1, MMP-2, MMP-8,
MMP-13, MMP-14, MMP-18, and MMP-22, catalyze the ﬁrst
committed step in extracellular matrix degradation by unwinding
and cleaving the triple helix of interstitial collagens (type
I–III)29–34. On the other hand, MMP-3 and MMP-9 only possess
the ability to bind to single-strand type I collagen. The collagen
cleavage site is similar for most MMPs, and the general motif
preceding the scissile bond (between Gly and Ile/Leu) has been
characterized as a four-triplet region rich in proline with one
always at the P3 position. It is important to recognize the ability
to unwind and cleave interstitial collagen in the triple helix form
as the main determinant of substrate speciﬁcity, rather than the
primary structure33,34.
Because of their signiﬁcant role in tumor angiogenesis,
invasion, and metastasis, MMPs have been targeted in poten-
tial therapeutic strategies for a number of disease conditions
including cancer, arthritis, glomerulonephritis, periodontal
disease, and ulcers34. Among them, MMP-2 and MMP-9 have
been used in the targeted activation of potential prodrugs35–38.
Model prodrugs have been reported to release, upon activation
by MMP-9, anthraquinone-type cytotoxic agents that are often
used in combination with conventional therapies for the treatment
of multiple myeloma37. L-Prolyl-N-(3-aminopropyl)-1-aminoan-
thraquinone, an adduct known to possess dual topoisomeraseN
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uliﬂoxacin by hPON1.
Substrates
Collagens (I, II, III, VII, VIII, and X); gelatin; aggrecan;
L-selectin; IL-1beta; proteoglycans; entactin; ovostatin;
MMP-2; MMP-9
Collagens (IV, V, VII, and X); gelatin
Collagens (III, IV, V, and IX); gelatin; aggrecan; perlecan;
decorin; laminin; elastin; caesin; osteonectin; ovostatin;
entactin; plasminogen; MBP; IL-1beta; MMP-2/TIMP-2;
MMP-7; MMP-8; MMP-9; MMP-13
Collagens (I, II, III, V, VII, VIII, and X); gelatin; aggrecan;
ﬁbronectin
Collagens (IV, V, VII, X, and XIV); gelatin; entactin;
aggrecan; elastin; ﬁbronectin; osteonectin; plasminogen;
MBP; IL-1beta
Collagens (I, II, III, IV, IX, X, and XIV); gelatin;
plasminogen; aggrecan; perlecan; ﬁbronectin; osteonectin;
MMP-9
Collagens (I-III); gelatin; casein; ﬁbronectin; laminin;
vitronectin; entactin; proteoglycans; MMP-2; MMP-13
Not known
Not known
Enzyme-mediated hydrolytic activation of prodrugs 147inhibitory activity in vivo, was coupled to an optimized substrate
of MMP-9 as shown in EV1 (11)37. Cleavage of EV1 by MMP-9
occurs between glycine and norvaline, resulting in the liberation of
an active inhibitor of topoisomerases.
Selective delivery of doxorubicin to tumor tissues was
investigated using its peptide conjugates as prodrugs activated
by the combined proteolytic action of MMP-2, MMP-9, and
MMP-14. Doxorubicin is a potent anthracycline used for the
treatment of various types of cancer. It causes cytotoxicity
through topoisomerase II-mediated DNA breaks. Coupling of
doxorudicin to several MMP-cleavable peptides generated a
series of prodrugs that were readily cleaved by MMP-2,
MMP-9, and MMP-14. For example, the prodrug Ac–Glu–
Pro–Cit–Gly–homo-Phe–Tyr–Leu–Dox (12) was cleaved by
MMP-2, MMP-9, and MMP-14 to generate a tripeptide–Dox
conjugate, which was subsequently degraded by extracellular
proteases to release Leu–doxorubicin as shown in Fig. 5. Leu–
doxorubicin was known to release doxorubicin upon further
proteolytic cleaveage. Prodrug testing in the ﬁbrosarcoma cell
line HT1080 expressing multiple MMPs and HT1080 xeno-
grafts in mice demonstrated the selective conversion of the
doxorubicin prodrug to free doxorubicin36. The prodrug also
exhibited a 10-fold increase in tumor/heart distribution ratio,
greater efﬁcacy and less toxicity as compared to doxorubicin.
2.6. Alkaline phosphatase
Alkaline phosphatase (AP, EC 3.1.3.1) is a metalloenzyme
(contains zinc and magnesium) with broad substrate speciﬁcity.
It catalyzes the removal of phosphate groups from a diverseH
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Figure 5 Activation of a peptide–doxorubicin pclass of compounds, including nucleotides, proteins, and
alkaloids. AP is ubiquitously expressed in many tissues with
the highest expression in the liver. The differential expression
of various AP isozymes in liver and bone has been used as a
diagnostic marker for various cancers and renal dysfunction39.
AP is believed to be responsible for the activation of several
clinically used phosphate prodrugs including fosﬂuconazole,
fosphenytoin, fosprepitant, amifostine, clindamycin phosphate,
estramustine phosphate, and etoposide phosphate. Most of these
prodrugs were developed to overcome the solubility problems of
parent drugs and are for parental administration while some are
for the targeted treatment of cancer. Amifostine (WR-2721, S-2
[3-aminopropylamino]-ethylphosphorothioic acid, 13) was devel-
oped as a protective agent against radiation- and chemotherapy-
induced cellular injury40. It is selectively activated in normal cells
by AP via dephosphorylation to afford the free thiol WR-1065,
which acts a free-radical scavenger (Fig. 6). In addition to free-
radical scavenging, the protective effect of amifostine has been
postulated to originate from DNA repair through hydrogen
donation from the free thiol group, and inhibition of DNA
damage. The protective effects of amifostine have been demon-
strated in preclinical species in the presence of platinum
compounds such as cisplatin. Following incubation of cisplatin
in salmon sperm DNA in the presence of 50-fold molar excess of
amifostine, WR-1065 and related compounds, a maximal 49%
reduction in platinum–DNA adduct formation was observed
with WR-106541. Clinically, the protective effects of amifostine
administration 30 min prior to chemotherapy have proven
effective although no proof-of-concept could be obtained in
in vivo animal studies.OH
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Yan-hui Yang et al.148AP-mediated prodrug activation has been applied to cancer
imaging and therapy. Such radio-detection of solid tumors
in vivo was demonstrated using the radioactive quinazolinone
phenol phosphate prodrug 125IQ2-P, the ammonium salt of
2-(20-phosphoryloxyphenyl)-6-[125I]iodo-4-(3H)-quinazolinone
(14). As shown in Fig. 6, the prodrug is hydrolyzed to a much
less water-soluble, radiolabeled quinazolinone 125IQ2-OH by
AP, which is overexpressed on the exterior surfaces of tumor
cell plasma membranes42. The quinazolinone molecule preci-
pitates and is concentrated and permanently trapped within the
extracellular spaces of targeted solid tumors. The prolonged
residence time of the quinazolinone molecule should permit the
noninvasive detection and therapy of tumors.
2.7. b-Glucuronidase
Human b-glucuronidase (EC 3.2.1.31) is a lysosomal enzyme
that plays an important role in the degradation of glucuronicOHOHO
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Figure 6 Activation of amifostine and 125IQ2-P by AP.acid-containing glycosaminoglycans, such as heparan sulfate,
chondroitin sulfate. and dermatan sulfate43. The function of
human b-glucuronidase is essential for the restructuring of the
extracellular matrix components and mutation in the b-
glucuronidase gene has been shown to cause a rare lysosomal
storage disease called mucopolysaccharidosis type-VII (Sly
syndrome)44. b-Glucuronidase is a tetrameric glycoprotein
with four identical subunits of 77 kDa and is localized in
lysosomes of the cell. The optimal pH for the activity of
human b-glucuronidase is around 4, while the physiological
pH of 7.4 leads to decreased enzyme activity43. Since endo-
genous extracellular b-glucuronidase is present at high levels in
necrotic tumors, glucuronide prodrugs could potentially be
used as a monotherapy. Moreover, in the case of non-necrotic
areas of tumors where the enzyme concentration is low,
exogenous b-glucuronidases can be delivered to these tumor
tissues using ADEPT and GDEPT strategies45.
The active site cavity of human b-glucuronidase consists of
three amino acid residues, Glu540, Glu451, and Tyr504. Among
them, Glu540 acts as a nucleophile, while Glu451 acts as an acid–
base catalyst or the proton donor46,47. Tyr504 is also important,
although its role is unclear. b-Glucuronidase have a broader
substrate speciﬁcity; almost any aglycone in a b-linkage can be
hydrolyzed to glucuronic acid43. One possible mechanism pro-
posed for the hydrolytic action by b-glucuronidase is illustrated
in Fig. 748.
Tumor tissues, including breast, lung and gastrointestinal tract
carcinomas, and melanomas have been shown to have increased
expression of b-glucuronidase as compared to normal tissues.
The high expression of the b-glucuronidase enzyme is localized
mainly in necrotic areas of the malignancies43. The liberation of
lysosomal b-glucuronidase extracellularly leads to the accumula-
tion of the enzyme in the extracellular matrix of the malignantO
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Enzyme-mediated hydrolytic activation of prodrugs 149tissues. Cancer tissues have been targeted by a wide variety of
glucuronide prodrugs exploiting the presence of high concentra-
tions of b-glucuronidase as the enzyme is not present in the
general circulation. BHAMG (15), a synthetic glucuronide
prodrug of aniline mustard, can be activated by Escherichia coli
b-glucuronidase49. Pyrrolo[2,1-c][1,4]-benzodiazepine-b-glucuro-
nide (16), a prodrug of DNA minor groove binder, has been
shown to be activated by b-glucuronidase50. HMR1826 (17),
where the glucuronide group is linked to doxorubicin as showed
in Fig. 8, has a Vmax of 635 mmol/(min mg) and a Km of
1.3 mmol/L as a substrate of b-glucuronidase43. Upon b-glucur-
onidase-catalyzed hydrolysis, the 4-hydroxybenzyl carbamate-
doxorubicin intermediate undergoes self-immolative 1,6-elimina-
tion to release the active doxorubicin drug.2.8. Human valacyclovirase
Human valacyclovirase (VACVase) is a highly speciﬁc a-
amino acid ester hydrolase. VACVase catalyzes the hydrolytic
activation of two clinically important antiviral nucleoside
prodrugs, valacyclovir and valganciclovir, to their correspond-
ing active drugs, acyclovir and ganciclovir51.
VACVase is expressed at a high level in human liver and
kidney and lower levels in intestines, heart, and skeletal
muscle52. Nucleoside analogs valacyclovir (18, VACV) and
valganciclovir (19, VGCV) are two typical prodrugs activated
by VACVase. Valacyclovir, the valyl ester prodrug ofO
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immolative linker.acyclovir (ACV), increases the oral bioavailability of ACV
3- to 5-fold53. In addition to activating valacyclovir and
valganciclovir, VACVase has been shown to hydrolyze the
prodrugs of a broad range of antiviral and anticancer nucleoside
analogs such as zidovudine, ﬂoxuridine, and gemcitabine52.2.9. Plasmin
Plasmin (EC 3.4.21.7) is an important serine protease present
in blood that degrades many blood plasma proteins, most
notablely, ﬁbrin clots. In humans, the plasmin protein is
encoded by the PLG gene. Plasmin is derived from plasmino-
gen, a circulating glycoproteins (91 kDa) present in plasma at
a concentration of 1.5 mmol/L54.
Plasmin is believed to be involved in migration, invasion,
and metastasis of tumor cells by catalyzing the breakdown of
extracellular matrix proteins55,56. Plasmin is predominantly
present in its inactive pro-enzyme form plasminogen in the
body. Active plasmin is formed locally at or near the surface
of tumor cells from cell-bound plasminogen activated by cell-
bound urokinase-type plasminogen activator (u-PA), pro-
duced by cancer or stroma cells57. In the general circulation,
urokinase and plasmin are inactivated by protease inhibitors
such as PAI-1 and a2-antiplasmin present in the blood. Many
tumor cell lines and tumor tissues have a signiﬁcantly higher
u-PA level than their normal counterparts58, and u-PA is a
strong prognostic factor for reduced survival and increasedO
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826) by b-glucuronidase followed by 1,6-elimination of the self-
Yan-hui Yang et al.150relapse in many types of tumors59,60. Therefore, plasmin is
considered a promising enzyme for the tumor-speciﬁc activa-
tion of anticancer prodrugs. Characteristic substrate tripep-
tides, D-Ala–Phe–Lys and D-Val–Leu–Lys, with a N-terminal
D-amino acid have been used in the design of potential
prodrugs for activation by plasmin. Examples include N-
nitroso-urea-based prodrug (20) with a substrate tripeptide
coupled via a cyclization linker61. As shown in Fig. 9, an
ethylene diamine and a mono-methylated ethylene diamine
serve to link the tripeptide substrates to N-nitroso-urea. In the
presence of plasminogen, the tripeptide segment is cleaved off
by plasmin and subsequent intramolecular cyclization leads to
the formation of imidazolidin-2-one with concomitant expul-
sion of the free parent drug.
Albumin-binding methotrexate prodrug was reported by
conjugation of albumin with the maleimide-linked peptide
methotrexate 2162. Plasmin cleavage between D-Ala–Phe–Lys
tripeptide and the lysine linker releases gMTX–eLys–OH,
which is an active cytotoxic agent. Anthracycline-based pro-
drug (22), formed by insertion of a cleavable linker between the
tripeptide substrate and doxorubicin, was shown to be stable in
Tris buffer and bovine serum, and is readily cleaved by
plasmin63. Paclitaxel prodrug (23) with a carbonate linker
was also designed to be selectively activated by plasmin64. The
paclitaxel-20-carbonate prodrug is stable in Tris buffer, and the
release of free paclitaxel through 1,6-elimination process was
shown to be instantaneous upon proteolysis by plasmin.2.10. Prostate-speciﬁc antigen
Prostate-speciﬁc antigen (PSA, EC 3.4.21.77) was ﬁrst identi-
ﬁed in human seminal plasma in 1969 (Fig. 11). PSA is a
glycoprotein composed of a single polypeptide chain with a
total mass of 33–34 kDa containing approximately 7% carbo-
hydrate65. PSA is primarily produced by prostate ductal and
acinar epithelium and is secreted into the lumen, where it
cleaves semenogelin I and II in the seminal coagulum66. PSA
has been shown to activate urokinase-type plasminogen acti-
vator, which is thought to be involved in cancer invasion and
metastasis67. PSA could also affect tumor spread by proteolytic
modulation of cell adhesion receptors68. Furthermore, PSA is
able to cleave insulin-like growth factor binding protein 3
(IGFBP-3) causing the release of active IGF-I, which could
enhance tumor growth69. However, other studies indicated that
PSA may inhibit tumor growth by generating antiangiogenic
angiostatin from plasminogen70,71.
The concentration of PSA in the prostate extracellular ﬂuid
is around 1.6–2.1 mmol/L (50–68 mg/mL) in normal prostateN N
R = D-Ala-Phe-Lys, D-Val-Leu-Lys 
R' = H, CH3
plasmin
O
ClRHN
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N
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H2N
N-nitroso-urea-based prodrugs (20)
Figure 9 Plasmin activation of Nand primary prostate cancer, where 80–90% of PSA is
enzymatically active72. However, intracellular PSA is enzyma-
tically inactive because of the presence of high concentration of
zinc ion. Normally, PSA is present in blood at very low levels
(o4.0 ng/mL). However, increased serum PSA levels are often
seen in prostate cancer patients, which are believed to be the
result of cellular PSA leak caused by the absence of a basement
membrane barrier that normally separates the prostate gland
from the surrounding stoma; this lack of conﬁnement is the
hallmark of invasive prostate cancer73,74. There is evidence that
serum PSA levels correlate well with the number of malignant
prostate cells, and high serum PSA levels suggest a high risk of
metastatic prostate cancer75. PSA has been approved by FDA
as a clinically important serological biomarker for the screen-
ing of prostate cancer. Most importantly, PSA present in
bloodstream lacks enzymatic activity because it forms an
inactive complex with protease inhibitors such as a1-antic-
hymotrpsin and a2-macroglobulin
76–78. Serum concentrations
of these protease inhibitors are 105–106 fold higher than serum
PSA levels and, therefore, are able to trap any active PSA
present74,79. The loss of enzymatic activity of serum PSA does
not affect the use of PSA as a serological marker because its
immunoreactivity is still maintained. These characteristics of
PSA, including speciﬁc production in the prostate tissue,
enzymatically active form only in extracellular environment,
enzymatically inactive form in serum and intracellular environ-
ment, and high concentration of PSA in malignant prostate
cancer cells, suggest that PSA can be used as a prodrug-
converting enzyme to activate anticancer prodrugs to achieve
selective therapeutic effects in prostate-derived cancer tissues.
Peptide-based prodrugs linking a substrate peptide sequence
to an anticancer drug have been reported for proteolytic
activation by PSA. Upon proteolytic cleavage by PSA, the
anticancer agent is then released locally in the microenviron-
ment that surrounds prostate cancer cells. The anticancer
selectivity is, therefore, achieved through the site-speciﬁc
activation of PSA. The peptide should be cleaved speciﬁcally
by PSA, and resist the hydrolytic actions of other enzymes;
thus, activation of the prodrugs will be localized in the prostate
and prostate-derived cancer tissues where 80–90% of PSA is
enzymatically active. Several short peptide sequences have been
identiﬁed as PSA-speciﬁc, including Ser–Lys–Leu–Gln–, His–
Ser–Ser–Lys–Leu–Gln–, and glutaryl-Hyp–Ala–Ser–Chg–Gln–,
all with a unique glutamine residue at P1 site
80,81. These
unique PSA substrate sequences were attached to anticancer
drugs with the dipeptide Ser–Leu or Leu as the linker to
improve the rate of PSA cleavage (e.g., glutaryl-Hyp–Ala–Ser–
Chg–Gln–Ser–Leu–Dox (24), N-morpholinocarbonyl-His–Ser–
Ser–Lys–Leu–Gln–Leu–Drug). The peptide–drug conjugatesN
Cl
NO
HN NR'
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Cl
N N
+
OH
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Cl
Cl
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Enzyme-mediated hydrolytic activation of prodrugs 151were shown to have increased therapeutic index in preclinical
prostate cancer models, validating the use of PSA as a
prodrug-converting enzyme82.
Various anticancer agents, including doxorubicin81,83, thapsi-
gargin84,85, vinblastine86,87, 5-ﬂuoro-20-deoxyuridine88, 3-hydroxy-
lapapchone, diazeniumdiolate89, nitrogen mustard90, protoxin91,
and paclitaxel92, have been used in prodrugs that showed selective
cytotoxicity against PSA-expressing cells. The peptide–
doxorubicin conjugate 24 was evaluated in phase I clinical trials82.
Another design of PSA substrate peptide conjugates of
anticancer drugs is to incorporate cleavable linkers between
PSA substrate peptide and anticancer drugs84,86,93,94. As
shown in Fig. 10, the parent drug FUDR could be released
through cyclization upon proteolytic cleavage of prodrug 25,
thus maintaining the potency and physiological property of
the parent drug.
Spontaneous conversion of 4-aminocyclophosphamide to
phosphoramide mustard under physiologiocal conditions was
demonstrated and exploited towards the design PSA-activated
prodrugs94. A series of 4-aminocylophosphamide prodrugs
(26) were synthesized by conjugating 4-aminocylophospha-
mide to the tetrapeptide Cbz–Ser–Ser–Phe–Tyr sequence, a
PSA substrate. The stereoselectivity of PSA-mediated cleavage
of the prodrugs was found to favor the cis-(2R, 4R)-conjugate,
which has a t1/2 of 12 min in the presence of PSA (Fig. 11).MeP-dR (27)
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Figure 12 The bioconversion of MeP-dR and F-dAdo by E. coli
PNP in GDEPT.2.11. Purine-nucleoside phosphorylase
Purine-nucleoside phosphorylase (PNP, EC 2.4.2.1) catalyzes
the cleavage of the glycosidic bond of ribo- and deoxyribonu-
cleosides, in the presence of inorganic orthophosphate (Pi) as a
second substrate, to generate the purine base and ribose(deox-
yribose)-1-phosphate. For the natural substrates, the reaction is
reversible95. PNPs are found in a broad range of organisms,
and divided into two main categories based on size, low
molecule mass homotrimers (about 80–100 kDa) and high
molecular mass homohexamers (about 110–160 kDa)95. Low
molecular mass homotrimers, mainly isolated from mammals,
are speciﬁc for catalysis of 6-oxopurines and their nucleosides,O
N
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Figure 11 Stereoselectivity of PSA cleavage of peptide 4-aminocyclo
mustard activated by PSA.while high molecular mass homohexamers, mainly found in
bacteria, accept as substrates both 6-oxo- and/or 6-aminopur-
ines and their nucleosides95. In mammals it is located especially
in the liver, brain, thyroid, kidney, and spleen. The highest
concentrations of the enzyme are found in the kidney, periph-
eral lymphocytes, and granulocytes39.
The selective cleavage of purine nucleoside analogs by E. coli
PNP is being evaluated as a possible suicide gene therapy
strategy (GDEPT) for the treatment of solid tumors. Excellent
antitumor activity has been demonstrated with 9-(2-deoxy-b-D-
ribofuranosyl)-6-methylpurine (MeP-dR, 27) against tumors
that express E. coli PNP96. The active metabolite 6-methylpur-
ine (MeP), can readily diffuse across cell membranes and kill
adjacent tumor cells that do not express E. coli PNP (Fig. 12)96.
2-Fluoro-20-deoxyadenosine (F-dAdo, 28) is another nucleoside
analog that is an excellent substrate for E. coli PNP97. It is
better tolerated by mice than MeP-dR, and the active form is
F-Ade, which is active against human tumor cells that do not
express E. coli PNP due to its conversion to toxic metabolites
and the subsequent inhibition of DNA synthesis97.O
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phosphamide conjugates as potential prodrugs of phosphoramide
Yan-hui Yang et al.1522.12. Carboxypeptidase G2
Glucarpidase under development as a chemoprotective agent
to neutralize the toxic effects of methotrexate is a recombinant
bacterial carboxypeptidase G2 (CPG2, EC 3.4.17.11). This
CPG2 from Pseudomonas RS-16 is a 42 kDa exopeptidase in
the aminoacylase-1/M20 family of enzymes that is not found
in mammals. The natural substrate of CPG2 is folic acid, but
it is capable of hydrolyzing glutamate from amidic98,99,
urethanic and ureidic bonds100,101, which allows it to be used
to activate synthetic prodrugs in GDEPT and ADEPT as
represented by the reaction shown in Fig. 13.
A series of CPG2-activated nitrogen mustard prodrugs has
been developed with various cytotoxic nitrogen mustards linked to
glutamate directly98,99,102–104 or through a self-immolative lin-
ker105,106. CPG2 catalyzes the hydrolytic activation of these
prodrugs, releasing glutamic acid and the parent cytotoxins,
including benzoic acid nitrogen mustards (BANM), aniline nitro-
gen mustards (ANM) and phenol nitrogen mustards (PNM).
4-[(2-mesyloxylethyl)(2-chloroethyl)amino]benzoyl-L-glutamic acid
(CMDA, 29) was the ﬁrst ADEPT prodrug evaluated clinically107.
A phase I ADEPT clinical trial of CDMA showed promising
results, with one patient showing a partial response and six
with stable disease for 4 months. However, the activated drug,
4-[(2-mesyloxylethyl)-(2-chloroethyl)amino]benzoic acid, had a
long half-life that resulted in dose-limiting myelosuppression due
to diffusion of the activated drug back into the circulation.
The pyrrolo[2,1-c][1,4] benzodiazepines (PBDs) are a family
of antitumor antibiotics produced by Streptomyces species108.
They exert their cytotoxicity by covalently bonding to the
exocyclic C2–NH2 group of guanine residues in the minor
groove of DNA through their N10–C11 imine functionality.
The more stable carbamate prodrugs are good substrates for
CPG2. The prodrug 30 was completely converted into the
cytotoxic parent PBD within 50 min of incubation with the
enzyme in vitro.
Methotrexate conjugates with amino acids or peptides
covalently linked to the a-carboxyl group of methotrexate
(MTX) are prodrug forms of the parent antifolate109–111.
When tested against UCLA-P3 human lung carcinoma cells
in vitro, the IC50 values for methotrexate–amino acid con-
jugates in the absence of CPG2 were in the micromolar range
(about 7.0 mmol/L). This value was much higher than the IC50
for MTX, which was in nanomolar range (28 nmol/L). When
incubated with UCLA-P3 human lung adenocarcinoma cells
treated with KS1/4-CPG2 conjugate (KS1/4 is a carcinoma-
speciﬁc monoclonal antibody), MTX–Phe (31) produced an
IC50 of 63 nmol/L. KS1/4–CPG2 conjugate treatment alone
produced no cytotoxicity and, in the absence of KS1/4-CPG2
conjugate, cells were much less susceptible to MTX–Phe
(IC50¼2.2 mmol/L).Figure 13 The mechanism of musta2.13. Penicillin amidase
Penicillin amidase (PA), also known as penicillin acylase, is
widely expressed in various microorganisms including, yeast,
fungi, and bacteria. It is a member of the N-terminal-
nucleophile hydrolase family, a group of enzymes sharing a
characteristic fold proximal to their active sites as well as a
nucleophilic residue at their N-terminus. The PA family
members hydrolyze a series of penicillins, and are subdivided
into three subtypes based on their substrate speciﬁcity, namely
penicillin V amidases (PVA, Type I; substrate: penicillin V,
phenoxymethylpenicillin), penicillin G amidase (PGA, Type
II; substrate: penicillin G, benzylpenicillin) and ampicillin
amidases (Type III; substrate: ampicillin). The E. coli isozyme
(EC 3.5.1.11) is a well-characterized, inexpensive and com-
mercially available Type II amidase commonly used for the
production of semisynthetic penicillins.
PGA is known to have broad substrate speciﬁcity; several
targeted prodrugs activated by PGA have been reported112,113.
The potent cytotoxin palytoxin exhibits activity against a wide
spectrum of cell types including ﬁbroblasts, lymphocytes,
erythrocytes and epithelial cells. It is cytotoxic against cells
expressing the Naþ–Kþ-ATPase associated toxin receptor.
The N-acyl palytoxin derivative, N-(40-hydroxyphenylacetyl)-
palytoxin (NHPAP, 32) was developed as a targeted prodrug
for PGA activation via ADEPT112. PGA was covalently
linked to the monoclonal antibody L6 mAb. Compared to
palytoxin, the prodrug was 1000 times less toxic to carcinoma
and lymphoma cells lacking PGA expression. NHPAP was
efﬁciently converted to palytoxin in H2981 cells expressing the
L6 antigen, and exhibited comparable cytotoxic activity to the
free drug (IC50 values were 0.06 and 0.01 nmol/L for NHPAP
and palytoxin, respectively).
The L6-PGA conjugate has also been used in the ADEPT-
assisted activation of doxorubicin and melphalan113. The
prodrugs, N-(phenylactemido)doxorubicin (33) and N-(pheny-
lacetyl)melphalan (34) were found to be 10- and 20-fold less
cytotoxic than free drugs in H2981 cancer lines lacking PGA.
Co-incubation with PGA increased the cytotoxicity of both
prodrugs due to PGA activation. For example, the IC50 values
of prodrug 33 were 2 mmol/L in the absence of PGA and
0.2 mmol/L in the presence of PGA, whereas the IC50 of
doxorubicin was 0.2 mmol/L in the same assay.2.14. b-Lactamase
b-Lactamase (EC 3.5.2.6) is a serine protease produced by
various bacteria; it catalyzes the hydrolysis of the b-lactam
moiety in penicillin and other similar b-lactam antibiotics to
b-amino acid. Based on primary sequences and metal ionrd prodrugs activated by CPG2.
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Enzyme-mediated hydrolytic activation of prodrugs 153requirement, b-lactamases have been grouped into four
classes. Classes A, C, and D utilize a serine residue in the
active site, whereas class B enzymes require an additional
catalytic zinc atom for activity. All of these enzymes contain
the active site serine residue as well as a conserved triad of
KS(T)G between the active site serine and the C terminus. The
class A b-lactamases are largely plasmid-encoded and are
widely distributed in both Gram-positive and Gram-negative
bacteria. The b-lactamases produced by Gram-positive organ-
isms are usually secreted enzymes. b-Lactamase may be
clinically beneﬁcial when orally administered to preserve the
natural intestinal ﬂora during the parenteral administration of
antibiotics.
The advantages of using b-lactamase in prodrug activation
in ADEPT are that the enzyme is not present in human cells
and that it is highly selective to the b-lactam containing
compounds. Cephalosporin has been widely utilized as the
core of b-lactamase-activated prodrugs due to its ability of
releasing the drug from C30 position following the cleavage of
b-lactam ring by b-lactamase.N
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Figure 15 Activation of glycosideAs shown in Fig. 14, opening of the b-lactam ring in
cephalosporin is initiated by the nucleophillic attack from the
hydroxyl group of the Ser70 side chain at the carbonyl carbon
(CQO) of the b-lactam ring. The drug attached to the C30
position represented as a leaving group (LG) is released by the
movement of electrons towards the thiazine ring of the cephem
core. It has been noted that the propensity for the drug release
depends on the leaving group ability of the drug molecule and
the stability of the linkage to the cephalosporin.
Vinca alkaloid derivative, LY233425, was also conjugated
to C30 position of cephalosporin through an alkyl thioether,N
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Enzyme-mediated hydrolytic activation of prodrugs 155which would leave as a thiol upon hydrolysis of the b-lactam
ring115. This vinca alkaloid prodrug 35 was shown to be 5 fold
less toxic than the free drug; but, it was equally potent as the
parent drug in the presence of b-lactamase.
A carbamate linker was used in a cephalosporin-taxol
prodrug, Protax (36)116. Because the C20 hydroxyl group oftaxol did not readily react with the p-nitrophenyl carbonate
attached to cephalosporin at C30, a GABA linker was used to
conjugate the C20-hydroxyl group of taxol with cephalosporin.
Since the C20-hydroxyl group is required for biological
activity, the prodrug will only be activated after the C20 linker
is removed.
Yan-hui Yang et al.1562.15. b-Galactosidase
E. coli b-galactosidase (EC 3.2.1.23), encoded by lacZ, has
been used in ADEPT. This enzyme is often used for histolo-
gical localization with 5-brom-4-chloro-3-indolyl-beta-D-
galactopyranoside (X-Gal) as the substrate. A glycoside
prodrug of duocarmycin analog (37) consists of the
(1S,10R)-methyl-seco-CBI-skeleton as effector, a dimethyla-
minoethoxyindole (DMAI) side chain for binding to the minor
groove of DNA and b-D-galactose as a promoiety117. This
prodrug has a rather low cytotoxicity with an IC50 of
3600 nmol/L but a very high cytotoxicity upon activation by
b-galactosidase to give a highly cytotoxic duocarmycin analog
(Fig. 15)118. Another example is the glycoside prodrug 38 of
doxorubicin, which was found to be stable in buffer and could
be readily converted to doxorubicin by b-galactosidase119.
2.16. Cytosine deaminase
Cytosine deaminase (CD, EC 3.5.4.1) catalyzes the hydrolytic
deamination of cytosine to uracil and 5-methylcytosine to
thymine. The enzyme has been found in bacteria and fungi,
where it plays an important role in pyrimidine salvage120.
However, no CD is present in mammalian cells, which utilize
the cytidine deaminase instead. Comparison of the active sites
of CD with other cytidine and deoxycytidylate deaminase
family, reveals a very similar interaction network between the
attacking water molecule, the zinc ion, the zinc ligands, and
the proton shuttle, suggesting a similar zinc-assisted deamina-
tion mechanism in the family120.
The yeast enzyme cytosine deaminase has also been widely
studied for GDEPT in conjunction with the antifungal agent
5-ﬂuorocytosine (39), which is converted by CD to the toxic
thymidylate synthase inhibitor 5-ﬂuorouracil as shown in
Fig. 16. This freely diffusible effector, already a drug of choice
for treating colon cancer, has much better bystander effects.
GDEPT model studies with CD/5-ﬂuorocytosine have focused
mainly on colon cancer models. Possible drawbacks of this
protocol include the relatively low potency of the effector,
coupled with its pronounced cell cycle selectivity121,122.3. Concluding remarks
Prodrugs have been very effective in solving problems of the
parent molecules to provide the desired physicochemical and
pharmaceutical properties for improved oral bioavailability,
patient acceptability, pharmacokinetic proﬁles, and target
speciﬁcity. There are many examples of prodrugs that are
used clinically. Enzymes play an important role in the
activation of many prodrugs although some prodrugs can be
activated solely through chemical reactions without involving
enzymes.
With the discovery of more compounds with desired
activity but suboptimal pharmaceutical properties, prodrugs
have become an increasingly important approach that can be
used to solve some of these problems. The structures of
compounds not in reactions were shown in Fig. 17. Knowing
the various enzymes that could potentially be used to activate
potential prodrugs will deﬁnitely help with the design process.
Most often endogenous enzymes can be effectively utilized
for the activation of prodrugs. With the recent shift of focus todeliver active drug molecules to a speciﬁc target tissue or
organ, non-endogenous enzymes have been employed for site-
speciﬁc activation of prodrugs. These novel approaches
include ADEPT, GDEPT, and VDEPT strategies for the
treatment of cancer. Enzymes used in these strategies include
some of the hydrolytic enzymes discussed above. These
approaches are very promising but are also very challenging.
There are still many problems to solve. With the advance of
new technologies, it is very likely we will see some of these
approaches become effective tools against various diseases.References
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